MedTrace Logo

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

NCT04379999 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-08-07

No results posted yet for this study

Summary

The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

Conditions

Interventions

DRUG

Atorvastatin 20mg

No history of colorectal cancer and no colorectal adenomas within 5 years.

DRUG

Atorvastatin 20mg AND Aspirin 325 mg

History of colorectal cancer and/or history of colorectal adenomas within 5 years.

Sponsors & Collaborators

  • Prevent Cancer Foundation

    collaborator OTHER

  • Fox Chase Cancer Center

    lead OTHER

Principal Investigators

  • Michael J Hall, MD, MS · Fox Chase Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2025-08-04
Completion
2025-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379999 on ClinicalTrials.gov